NYLIM
LYEL icon

New York Life Investment Management’s Lyell Immunopharma LYEL Stock Holding History

New York Life Investment Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,190
Closed -$410K – 1128
2024
Q1 		$410K Buy
9,190
+1,817
+25% +$77.8K ﹤0.01% 804
2023
Q4 		$286K Sell
7,373
-170
-2% -$6.12K ﹤0.01% 1237
2023
Q3 		$222K Sell
7,543
-1,189
-14% -$56.5K ﹤0.01% 1261
2023
Q2 		$555K Sell
8,732
-1,362
-13% -$75.4K 0.01% 664
2023
Q1 		$476K Buy
+10,094
New +$540K 0.01% 981

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's LYEL Position: Q2 2024 in Review

New York Life Investment Management sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 9,190 shares — an estimated $410K sold.

New York Life Investment Management first reported a position in LYEL in Q1 2023 and held it in 5 quarters. The position peaked at $555K in Q2 2023. 119 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • New York Life Investment Management reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 9,190 Lyell Immunopharma shares in Q2 2024, an estimated $410K.
  • New York Life Investment Management first reported a position in Lyell Immunopharma in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Lyell Immunopharma position peaked at $555K in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.